News HIV/AIDS

A group of community organisations working on HIV prevention
have called for the NHS to speed up it processes and make pre-exposure
prophylaxis (PrEP) available to those at the highest risk of acquiring HIV. The
organisations point to the continued hig…

A group of community organisations working on HIV prevention
have called for the NHS to speed up it processes and make pre-exposure
prophylaxis (PrEP) available to those at the highest risk of acquiring HIV. The
organisations point to the continued hig…

Most people with chronic hepatitis B who are
treated with tenofovir for eight years continued to maintain viral suppression,
researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in
Bo…

Nella Giornata mondiale contro Aids, Apple lancia una campagna di sostegno all’iniziativa ‘Red’ del cantante Bono. Disponibili 25 app tra le più popolari, il cui ricavato sarà devoluto al Fondo globale per la lotta contro la malattia.

A US study
presented at last month’s HIV Research for Prevention conference found generally
positive responses among people with HIV and clinic staff to a trial that used
$70 gift tokens as an incentive for people to attend clinic regularly,
refill their HIV treatment drug prescriptions, and maintain an undetectable viral load.
However, the
study found

 
A 12-week oral combination
of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high
sustained virological response rates for people with difficult-to-treat HCV
genotype 3 and other genotypes, according to phase 2 study findings presented at
the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration

The UK’s annual epidemiological report, released yesterday,
shows that the country already provides HIV treatment to 90% of people attending
clinical services and that 90% of those on treatment have an undetectable viral
load. But the country has a long way to go in ensuring that people with HIV
are aware of their HIV

«Le opzioni terapeutiche di cui disponiamo, incluse le più recenti, nonostante la loro indiscutibile efficacia, lasciano aperti numerosi problemi: sono attive principalmente contro i genotipi 1 e 4 di HCV, e molto meno efficaci per circa un terzo dei pazienti, quelli con genotipo 2 e 3, e non danno risposte soddisfacenti in presenza di cirrosi compensata e scompensata.

An all-oral regimen of
grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without
ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates
for treatment-naive and treatment-experienced people with genotype 1 hepatit…

Sofosbuvir/ledipasvir without
ribavirin and AbbVie’s 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both
produced high sustained virological response rates for people with hepatitis C
virus (HCV) genotype 4, according to a pair of studies presente…